Metastatic Cervical Cancer clinical trials

Explore recruiting metastatic cervical cancer clinical trials.

Recruiting metastatic cervical cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Cervical Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Sweden, Czechia, Finland, Netherlands, Hungary, Norway +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Greece, Ireland, France, Belgium, Czechia, Hungary +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metastatic Cervical Cancer trials by city

Metastatic Cervical Cancer clinical trials

Recruiting metastatic cervical cancer studies right now

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

AB122 Platform Study

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Study of NX-1607 in Adults With Advanced Malignancies

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Also recruiting in Europe

PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Metastatic Cervical Cancer trials by city

Other conditions